KBC Securities - MAAT PHARMA SA (MAAT) MaaT Pharma MaaT013 EAP data shows continued benefit, phase 3 topline in Jan 2025

Report

KBC Securities

Jacob Mekhael

MaaT Pharma MaaT013 EAP data shows continued benefit, phase 3 topline in Jan 2025

MaaT presented updated results from the early access program (EAP) for lead candidate MaaT013 (microbiome therapy, enema formulation) in aGvHD in Europe during the American Society of Hematology (ASH) conference. We continue to be encouraged by the strong responses observed in the subset of 58 patients resembling the population enrolled in the phase 3 (ARES) trial, which in our view provides comfort ahead of the upcoming topline readout in January 2025. We reiterate our € 14 TP and BUY rating.

10/12/2024 1 EN

Underlying

MAAT PHARMA SA

See profile

FR0012634822 Euronext Paris France

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Jacob Mekhael

Other Reports on these Companies

KBC Securities

MaaT Pharma Positive DSMB safety analysis for MaaT033 phase 2 in allo-HSCT

MaaT announced the positive outcome of a key DSMB safety interim analysis for the phase 2b trial (PHOEBUS), which compares the efficacy and safety of MaaT033 (microbiome therapy, oral capsule) to placebo in patients undergoing an allogeneic hematopoietic stem cell transplantation (allo-HSCT). We are encouraged by the DSMB outcome, particularly in the context that allo-HSCT is a high risk patient population, and see this as supportive of MaaT033´s good safety profile. We note that MaaT033 is next in line after lead product MaaT013 in aGvHD, and offers scalability via its oral administration all...

April 8, 2025 April 8, 2025 1 EN

KBC Securities

MaaT Pharma To present preclinical data on MaaT034 at AACR

MaaT will present new non-clinical data on MaaT034 (donor independent microbiome therapy) at the American Association for Cancer Research (AACR) conference, taking place on 25-30 April. The results demonstrate MaaT034's potential as a combination therapy to improve responses to checkpoint inhibitors in solid tumours. Being co-cultured means MaaT034 is donor-independent, which offers the scale required for the larger solid tumour market. Initial data from the phase 2 placebo-controlled trial of lead product MaaT013 (donor dependent) in combination with checkpoint inhibitors in metastatic melano...

April 1, 2025 April 1, 2025 1 EN

KBC Securities

Morning Notes : COLR BB, FLOB BB, KIN BB, MAAT FP, ONWD BB

: COLR BB, FLOB BB, KIN BB, MAAT FP, ONWD BB

April 1, 2025 April 1, 2025 1 EN

Belysse 1Q25 revenue -4.3%, reflecting weaker performance in Europe

1Q revenue dropped by 4.3%, reflecting weaker demand in Europe against a tough comparable. 1Q adjusted EBITDA declined, due to a lower performance in Europe despite growth in the US. After the weaker than expected 1Q performance, we have lowered our FY25/26 adjusted EBITDA forecasts by c. 5%. Valuation continues to look attractive and prompts us to reiterate our Accumulate rating and € 1.6 target price.

20h / 39m 20h / 39m 1 EN

Lynn Hautekeete

Lynn Hautekeete

Qrf City Retail 1Q25 trading update: casa and two new independent directors

QRF's 2025 trading update focusses on the CASA bankruptcy and appointment of 2 new independent directors: Pieter Bogaert (Director of Real Estate & Development and Compliance Officer at Xior) and Kara De Smet (CFO of Retail Estates). Casa represents 6.7% of total contractual rents. Four out of five locations have been re-let at similar contractual rents. There is however a transition period before the bankruptcy is finalised which implies rental loss. 2025 will be a transition year with CASA and the redevelopment of 2 assets in Ghent. This is partially offset by the office income (EUR 534k ann...

21h / 49m 21h / 49m 1 EN

Livio Luyten

Livio Luyten

Texaf Q1 FY25: Solid Performance In RE; New Projects Boosting Growth

During Q1 FY25, TEXAF's real estate segment delivered robust performance despite DRC's challenging geopolitical environment, achieving near 100% occupancy and €7.7m in rental income from Kinshasa's residential and office properties, up 29% YoY. Growth was driven by the new Promenade des Artistes (94 apartments) and 6,000 m² of additional coworking/private office space at Silikin Village Phase III, with private office occupancy exceeding 90% (75%/35% for fixed/flexible coworking spaces). Like-for-like rental income rose 6%. The sandstone quarry in Kinshasa (Carrigres) saw sales drop 52% versus ...

21h / 51m 21h / 51m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

MaaT Pharma MaaT013 EAP data shows continued benefit, phase 3 topline in Jan 2025

We are a financial services provider for several types of professional clients, each with distinct needs.

MaaT Pharma Positive DSMB safety analysis for MaaT033 phase 2 in allo-HSCT

MaaT Pharma To present preclinical data on MaaT034 at AACR

Morning Notes : COLR BB, FLOB BB, KIN BB, MAAT FP, ONWD BB

Belysse 1Q25 revenue -4.3%, reflecting weaker performance in Europe

Qrf City Retail 1Q25 trading update: casa and two new independent directors

Texaf Q1 FY25: Solid Performance In RE; New Projects Boosting Growth

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe